Malunga-nomhlaza / unyango / ulingo lweklinikhi / isifo / i-uterine-sarcoma / unyango
Unyango lwezilingo zovavanyo lwesibeleko sesibeleko
Uvavanyo lwezonyango zizifundo zophando ezibandakanya abantu. Uvavanyo lweklinikhi kolu luhlu lonyango lwe-sarcoma yesibeleko. Zonke izilingo ezikuluhlu ziyaxhaswa yi-NCI.
Ulwazi olusisiseko lwe-NCI malunga nolingo lweklinikhi luchaza iintlobo kunye nezigaba zovavanyo kunye nendlela ezenziwa ngayo. Uvavanyo lwezonyango lujonga iindlela ezintsha zokuthintela, ukufumanisa, okanye ukunyanga izifo. Unokufuna ukucinga ngokuthatha inxaxheba kuvavanyo lweklinikhi. Thetha nogqirha wakho ngoncedo ekunqumeni ukuba ikulungele na.
Izilingo 1-5 ku-5
I-Nivolumab ekunyangeni abaguli abane-Metastatic okanye i-Uterine Cancer ephindaphindiweyo
Isigaba sesibini sokuvavanywa kwesilingo sokuba isebenza njani i-nivolumab ekunyangeni abaguli abanomhlaza wesibeleko osasazeke kwezinye iindawo emzimbeni (metastatic) okanye ubuye emva kwexesha lokuphucuka (okuphindayo). I-Immunotherapy ene-monoclonal antibodies, efana ne-nivolumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa amandla eeseli zethumba ukukhula kunye nokusasazeka.
Indawo: Iindawo ezi-7
Ikhosi emfutshane yelungu lobufazi i-Cuff Brachytherapy ekunyangeni abaguli abanesigaba se-II-Endometrial Cancer
Olu phononongo lwesigaba se-III solingo esingahleliwe sifundisa ikhosi emfutshane yecuff brachytherapy ukubona ukuba isebenza njani xa kuthelekiswa nomgangatho wokhathalelo lobufazi ubukrakratherapy ekunyangeni abaguli abanomhlaza we-I-II womhlaza we-endometrium. Ikhosi emfutshane yecuff langs brachytherapy, ekwabizwa ngokuba lonyango lwangaphakathi lwemitha, isebenzisa (ngaphezulu kwexesha elifutshane) izinto ezinemitha ebangwa ngqo ngaphakathi okanye kufutshane nethumba kwinxalenye ephezulu yelungu lobufazi ukubulala iiseli zesisu.
Indawo: Iindawo ezi-7
Uhlalutyo olukhawulezileyo kunye noVavanyo lweempendulo zokudityaniswa kweearhente ezichasene neplastic kwiRare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib kunye nePaclitaxel
Imvelaphi: Abantu abanomhlaza onqabileyo bahlala bekhetha unyango olunomda. Ibhayoloji yomhlaza onqabileyo ayiqondwa kakuhle. Abaphandi bafuna ukufumana unyango olungcono kule mihlaza. Bafuna ukuvavanya amachiza ama-2 athi, athathwe ngokwahlukeneyo, ancede abantu abanomhlaza ongaqhelekanga. Bafuna ukubona ukuba la machiza xa edibene angenza umhlaza onqabileyo unciphe okanye uyeke ukukhula. Injongo: Ukufunda ukuba i-nilotinib kunye ne-paclitaxel ziya kunceda abantu abanomhlaza onqabileyo. Ukufaneleka: Abantu abaneminyaka eli-18 nangaphezulu abanesifo somhlaza esinqabileyo, esiqhubele phambili emva kokufumana unyango oluqhelekileyo, okanye ekungekho lonyango lusebenzayo. Uyilo: Abathathi-nxaxheba baya kuvavanywa ngembali yezonyango kunye novavanyo lomzimba. Baza kuvavanywa igazi nomchamo. Baya kuba novavanyo lokukhulelwa xa kufuneka njalo. Baya kuba ne-electrocardiogram ukujonga iintliziyo zabo. Baza kuba nemifanekiso yokulinganisa ukulinganisa amathumba abo. Abathathi-nxaxheba baya kuphinda uvavanyo lokuvavanywa ngexesha lofundo. Abathathi-nxaxheba baya kufumana i-nilotinib kunye ne-paclitaxel. Amachiza anikezelwa kwimijikelo yeentsuku ezingama-28. I-Nilotinib yi-capsule ethathwe ngomlomo kabini ngemini. I-Paclitaxel iya kunikwa ngaphakathi ngaphakathi ngomgca wendlela okanye kumda osembindini kube kanye ngeveki kwiiveki zokuqala ezi-3 kumjikelo ngamnye. Abathathi-nxaxheba baya kugcina idayari yamayeza. Baza kulandelela xa bethatha amayeza ophando kunye naziphi na iziphumo ebezingalindelekanga abanokuba nazo. Abathathi-nxaxheba banakho ukuba ne-tumor biopsies. Abathathi-nxaxheba banokuhlala kuphononongo de isifo sibe sibi kakhulu okanye babe neziphumo ebezingalindelekanga ezinganyamezelekiyo. Abathathi-nxaxheba baya kuba nefowuni yokulandelela malunga neentsuku ezingama-30 emva kokuthatha idosi yokugqibela yamachiza okufunda. Abathathi-nxaxheba baya kufumana i-nilotinib kunye ne-paclitaxel. Amachiza anikezelwa kwimijikelo yeentsuku ezingama-28. I-Nilotinib yi-capsule ethathwe ngomlomo kabini ngemini. I-Paclitaxel iya kunikwa ngaphakathi ngaphakathi ngomgca wendlela okanye kumda osembindini kube kanye ngeveki kwiiveki zokuqala ezi-3 kumjikelo ngamnye. Abathathi-nxaxheba baya kugcina idayari yamayeza. Baza kulandelela xa bethatha amayeza ophando kunye naziphi na iziphumo ebezingalindelekanga abanokuba nazo. Abathathi-nxaxheba banakho ukuba ne-tumor biopsies. Abathathi-nxaxheba banokuhlala kuphononongo de isifo sibe sibi kakhulu okanye babe neziphumo ebezingalindelekanga ezinganyamezelekiyo. Abathathi-nxaxheba baya kuba nefowuni yokulandelela malunga neentsuku ezingama-30 emva kokuthatha idosi yokugqibela yamachiza okufunda. Abathathi-nxaxheba baya kufumana i-nilotinib kunye ne-paclitaxel. Amachiza anikezelwa kwimijikelo yeentsuku ezingama-28. I-Nilotinib yi-capsule ethathwe ngomlomo kabini ngemini. I-Paclitaxel iya kunikwa ngaphakathi ngaphakathi ngomgca wendlela okanye kumda osembindini kube kanye ngeveki kwiiveki zokuqala ezi-3 kumjikelo ngamnye. Abathathi-nxaxheba baya kugcina idayari yamayeza. Baza kulandelela xa bethatha amayeza ophando kunye naziphi na iziphumo ebezingalindelekanga abanokuba nazo. Abathathi-nxaxheba banakho ukuba ne-tumor biopsies. Abathathi-nxaxheba banokuhlala kuphononongo de isifo sibe sibi kakhulu okanye babe neziphumo ebezingalindelekanga ezinganyamezelekiyo. Abathathi-nxaxheba baya kuba nefowuni yokulandelela malunga neentsuku ezingama-30 emva kokuthatha idosi yokugqibela yamachiza okufunda. I-Paclitaxel iya kunikwa ngaphakathi ngaphakathi ngomgca wendlela okanye kumda osembindini kube kanye ngeveki kwiiveki zokuqala ezi-3 kumjikelo ngamnye. Abathathi-nxaxheba baya kugcina idayari yamayeza. Baza kulandelela xa bethatha amayeza ophando kunye naziphi na iziphumo ebezingalindelekanga abanokuba nazo. Abathathi-nxaxheba banakho ukuba ne-tumor biopsies. Abathathi-nxaxheba banokuhlala kuphononongo de isifo sibe sibi kakhulu okanye babe neziphumo ebezingalindelekanga ezinganyamezelekiyo. Abathathi-nxaxheba baya kuba nefowuni yokulandelela malunga neentsuku ezingama-30 emva kokuthatha idosi yokugqibela yamachiza okufunda. I-Paclitaxel iya kunikwa ngaphakathi ngaphakathi ngomgca wendlela okanye kumda osembindini kube kanye ngeveki kwiiveki zokuqala ezi-3 kumjikelo ngamnye. Abathathi-nxaxheba baya kugcina idayari yamayeza. Baya kulandelela xa bethatha amayeza ophando kunye naziphi na iziphumo ebezingalindelekanga abanokuba nazo. Abathathi-nxaxheba banakho ukuba ne-tumor biopsies. Abathathi-nxaxheba banokuhlala kuphononongo de isifo sibe sibi kakhulu okanye babe neziphumo ebezingalindelekanga ezinganyamezelekiyo. Abathathi-nxaxheba baya kuba nefowuni yokulandelela malunga neentsuku ezingama-30 emva kokuthatha idosi yokugqibela yamachiza okufunda.
Indawo: Amaziko kaZwelonke eKliniki, eBethesda, eMaldin
I-Cabozantinib kunye neTemozolomide yonyango lwe-Leyomyosarcoma engabonakaliyo okanye iMetastatic okanye enye i-Soft Tissue Sarcoma
Isigaba sesibini sokuvavanywa kwesilingo sendlela esebenza ngayo i-cabozantinib kunye ne-temozolomide ekunyangeni abaguli abane-leiomyosarcoma okanye ezinye iiscoma zethishu ezithambileyo ezingenakususwa ngotyando (olungenakulinganiswa) okanye olunwenwe kwezinye iindawo emzimbeni (metastatic). I-Cabozantinib inokumisa ukukhula kweeseli zesisu ngokuthintela ezinye ii-enzymes ezifunekayo ekukhuleni kweseli. Iziyobisi ezisetyenziswa kwi-chemotherapy, njenge-temozolomide, zisebenza ngeendlela ezahlukeneyo ukunqanda ukukhula kweeseli zethumba, nokuba kungokubulala iiseli, ngokuzinqanda ekwahluleni, okanye ngokuzinqanda zisasazeke. Ukunika i-cabozantinib kunye ne-temozolomide kunokusebenza ngcono kunaye kuphela ekunyangeni abaguli abane-leiomyosarcoma okanye enye i-sarcoma ethambileyo. ICabozantinib sisiyobisi sophando,
Indawo: Iindawo ezi-7
I-Doxorubicin, i-AGEN1884, kunye ne-AGEN2034 yoNyango lwe-Advanced or Metastatic Soft Tissue Sarcoma
Isigaba sesibini sokuvavanywa kwesilingo sokuba i-doxorubicin kunye ne-AGEN1884 kunye ne-AGEN2034 zisebenza njani ekunyangeni abaguli abane-sarcoma ethambileyo esasazeke kwezinye iindawo emzimbeni (phambili okanye kwimetastatic). Iziyobisi ezisetyenziswa kwi-chemotherapy, njenge-doxorubicin, zisebenza ngeendlela ezahlukeneyo ukunqanda ukukhula kweeseli zethumba, nokuba kungokubulala iiseli, ngokuzinqanda zisahlule, okanye ngokuzinqanda zisasazeke. Unyango lwe-Immunotherapy olunee-antibodies ze-monoclonal, ezinje nge-AGEN1884 kunye ne-AGEN2034, lunokunceda amajoni omzimba ahlasele umhlaza, kwaye anokuphazamisa amandla eeseli zethumba ukukhula nokukhula. Ukunika i-doxorubicin, i-AGEN1884, kunye ne-AGEN2034 kunokusebenza ngcono ekunyangeni abaguli abane-sarcoma ethambileyo yesithambo xa kuthelekiswa ne-doxorubicin yodwa.
Indawo: ' KwiYunivesithi yaseColorado, eDenver, eColorado
Nika amandla ukuphinda uzihlaziye izimvo